Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Rokotetutkimuskeskus Finvac Oy

Research site

Finland Rantakatu 16, 67100 Kokkola, Finland

  • 2 trials recruiting
  • Influenza · Influenza immunisation · Meningococcal infection
  • Adults and children

About Specializations

Rokotetutkimuskeskus Finvac Oy in Kokkola, Finland specialises in clinical trials of conditions such as Influenza, Influenza immunisation, Meningococcal infection, Pneumococcal infection, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory Syncytial Virus and Respiratory Tract Diseases

At Rokotetutkimuskeskus Finvac Oy in Kokkola, clinical research in respiratory tract diseases focuses on RSV prevention and protection for infants and children at higher risk of severe illness. These studies are aimed at evaluating how well new preventive approaches work and how safe and well tolerated they are.

  • Prevention of RSV infection in infants and children at increased risk
  • Testing the effectiveness of new RSV therapies and vaccines
  • Assessing safety and tolerability in young participants

The site contributes to research on reducing RSV-associated lower respiratory disease and improving protection during the RSV season.

Pneumococcal Infections and Bacterial Infections

This clinic also supports studies in bacterial infections, especially pneumococcal disease, with a strong emphasis on prevention in young children. The research is designed to understand immune response and safety for candidate vaccines intended to help reduce infection risk.

  • Studying pneumococcal infections in healthy toddlers
  • Evaluating vaccine safety and immune response
  • Supporting prevention of serious bacterial respiratory illness

These trials help build evidence for better protection against common childhood pneumococcal disease.

Virus Diseases and Immune System Processes

Research at this laboratory and testing facility includes broader work on virus diseases and how the immune system responds to preventive treatments. The main goal is to generate evidence on safety, immune response, and clinical benefit for new vaccines and antibody-based approaches.

  • Exploring prevention of viral infections in infants and toddlers
  • Measuring immune response to candidate vaccines
  • Evaluating whether new preventive options reduce disease burden

The work reflects a clear focus on advancing infectious disease prevention through child-centered clinical research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Rantakatu 1667100 KokkolaFinland
Open in maps ↗
Recruiting now
2 trials
Conditions studied
12

More sites in KokkolaFinland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

20 clinical trials

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:GlaxoSmithKline Biologicals

Beta haemolytic streptococcal infection

Recruiting

A Study of Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine in Healthy Pregnant Women and Their Infants

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:GROUP B STREPTOCOCCUS CAPSULAR POLYSACCHARIDE IB CONJUGATED TO DIPHTHERIA TOXIN CRM197
  • Sponsor:Pfizer Inc.

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Not yet recruiting
Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Sanofi Pasteur Inc.

Metapneumovirus infection

Not yet recruiting

Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:IVX-121
  • Sponsor:AstraZeneca AB

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine for Respiratory Syncytial Virus in Adults Aged 60 and Older

Not recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Lyme disease

Not recruiting

Study on the Effectiveness and Safety of the VLA15 Vaccine for Preventing Lyme Disease in Healthy Individuals Aged 5 and Older

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:BORRELIA BURGDORFERI, SEROTYPE 1, OUTER SURFACE PROTEIN A FUSED VIA A LINKER TO BORRELIA BURGDORFERI, SEROTYPE 2, OUTER SURFACE PROTEIN A
  • Sponsor:Pfizer Inc.

Cytomegalovirus immunisation

Not recruiting

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Moderna Therapeutics Inc.

Meningococcal infection

Not recruiting

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
  • Sponsor:GlaxoSmithKline Biologicals

Influenza immunisation

Not recruiting

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
  • Sponsor:Abbott Biologicals B.V.

Meningococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a Booster Dose of MenACYW Conjugate Vaccine in Children and Adolescents Previously Vaccinated for Meningococcal Infection

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Tetanus toxoid
  • Sponsor:Sanofi Winthrop Industrie

Pneumococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal oligosaccharide serotype 18C conjugated to CRM197
  • Sponsor:Sanofi Pasteur Inc.

Study on the Safety and Effectiveness of Clesrovimab and Palivizumab for Preventing Severe RSV in Infants and Children at High Risk

Not recruiting
Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Clesrovimab
  • Sponsor:Merck Sharp & Dohme LLC
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.